# EDGAR Filing Document

**Accession Number:** 0001560293
**File Stem:** 0001213900-26-015556
**Filing Date:** 2026-2
**Character Count:** 26265
**Document Hash:** 2f51fddade4e38bde67ca773ca2f9da1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-015556.hdr.sgml**: 20260212

**ACCESSION NUMBER**: 0001213900-26-015556

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260212

**DATE AS OF CHANGE**: 20260212

**EFFECTIVENESS DATE**: 20260212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tenon Medical, Inc.
- **CENTRAL INDEX KEY:** 0001560293
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 455574718
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293417
- **FILM NUMBER:** 26626135

**BUSINESS ADDRESS:**
- **STREET 1:** 104 COOPER CT.
- **CITY:** LOS GATOS
- **STATE:** CA
- **ZIP:** 95032
- **BUSINESS PHONE:** (408) 649-5760

**MAIL ADDRESS:**
- **STREET 1:** 104 COOPER CT.
- **CITY:** LOS GATOS
- **STATE:** CA
- **ZIP:** 95032

**As filed with the Securities and Exchange Commission on February 12, 2026**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER**

**THE SECURITIES ACT OF 1933**

**TENON MEDICAL, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **3841** | **45-5574718** |
| (State or other jurisdiction of<br> incorporation or organization) | (Primary Standard Industrial<br> Classification Code Number) | (I.R.S. Employer<br> Identification No.) |

---

**104 Cooper Court**

**Los Gatos, CA 95032**

**(408) 649-5760**

(Address of Principal Executive Offices)

**Tenon Medical, Inc. 2022 Equity Incentive Plan**

(Full title of the plan)

**Steven M. Foster**

**Chief Executive Officer and President**

**Tenon Medical, Inc.**

**104 Cooper Court**

**Los Gatos, CA 95032**

(Name and Address of Agent For Service)

**(408) 649-5760**

(Telephone number, Including Area Code, of Agent For Service)

***Copies of all communications, including all communications sent to the agent for service, should be sent to:***

**Ross D. Carmel, Esq.**

**Jeffrey P. Wofford, Esq.**

 **Anna Chaykina, Esq.<br> Sichenzia Ross Ference Carmel LLP<br> 1185 Avenue of the Americas, 31<sup>st</sup> Floor**

**New York, NY 10036<br> (646) 838-1310**

**Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.**

---

| | |
|:---|:---|
| **Large accelerated filer** ☐ | **Accelerated filer** ☐ |
| **Non-accelerated filer** ☒ | **Smaller reporting company** ☒ |
|  | **Emerging Growth Company** ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**This Registration Statement will become effective upon filing in accordance with Rule 462(a) under the Securities Act.**

**EXPLANATORY NOTE**

**REGISTRATION OF ADDITIONAL SECURITIES** 

This Registration Statement on Form S-8 (the "**Registration Statement**") registers 445,100 additional shares of common stock of Tenon Medical, Inc., Delaware corporation, (the "**Registrant**") to be issued pursuant to the Registrant's Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended (the "**2022 Plan**").

Pursuant to General Instruction E of Form S-8 under the Securities Act of 1933, as amended ("**Securities Act**"), this Registration Statement consists only of those items required by General Instruction E to Form S-8. Accordingly the Registrant incorporates by reference into this Registration Statement the contents of (1) the registration statement on Form S-8 (File No. 333-268360), filed with the Securities and Exchange Commission (the "**SEC**") on November 15, 2022, relating to the registration of 29,092 shares of Registrant's common stock, par value $0.001 per share ("**Common Stock**") authorized for issuance under the 2022 Plan, (2) the registration statement on Form S-8 (File No. 333-271778), filed with the SEC on May 9, 2023, relating to the registration of additional 5,618 shares of Common Stock authorized for issuance under the 2022 Plan, and (3) the registration statement on Form S-8 (File No. 333-290808), filed with the SEC on October 10, 2025, in each case, except for Items 3 and 8, which are being updated by this Registration Statement.

Since October 10, 2025, the number of shares of Common Stock reserved and available for issuance under the 2022 Plan has been increased by 445,100 shares pursuant to an automatic increase under the 2022 Plan as of January 1, 2026. This Registration Statement provides for the registration of these additional 445,100 shares of Common Stock, that are reserved and available for issuance under the 2022 Plan and have not been registered by the Registrant pursuant to previously filed registration statements on Form S-8.

The Common Stock share amounts stated above are presented on a post-split basis and reflect the 1-for-10 reverse stock split effected by the Registrant on November 2, 2023 and the 1-for-8 reverse stock split effected by the Registrant on September 6, 2024.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The Registrant is subject to the informational and reporting requirements of Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"). The following documents, which are previously filed with the SEC, are incorporated into this Registration Statement by reference:

(a) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/1560293/000101376225002734/ea0234739-10k_tenon.htm) for the year ended December 31, 2024, filed with the SEC on March 26, 2025;

(b) the Registrant's Quarterly Reports on Form 10-Q for the periods ended March 31, 2025, June 30, 2025, and September 30, 2025, filed with the SEC on [May 13, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000121390025042714/ea0240286-10q_tenon.htm), [August 13, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000121390025075652/ea0251411-10q_tenon.htm), and [November 13, 2025](https://www.sec.gov/Archives/edgar/data/1560293/000121390025109961/ea0263628-10q_tenon.htm), respectively;

(c) the Registrant's Current Reports on Form 8-K filed with the SEC on [March 12, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000121390025023304/ea0234065-8k_tenon.htm), [March 27, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000101376225003341/ea0235831-8k_tenon.htm), [March 28, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000101376225004228/ea0236016-8k_tenon.htm), [August 7, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000121390025072781/ea0252007-8k_tenon.htm) (as amended on [October 17, 2025](https://www.sec.gov/Archives/edgar/data/1560293/000121390025100037/ea0261583-8ka1_tenon.htm)), [September 23, 2025](http://www.sec.gov/Archives/edgar/data/1560293/000121390025090627/ea0258406-8k_tenon.htm), [October 16, 2025](https://www.sec.gov/Archives/edgar/data/1560293/000121390025099596/ea0261386-8k_tenon.htm), [November 17, 2025,](https://www.sec.gov/Archives/edgar/data/1560293/000121390025111522/ea0265746-8k_tenon.htm) and [February 6, 2026](https://www.sec.gov/Archives/edgar/data/1560293/000121390026013278/ea0275920-8k_tenon.htm); and

(d) The description of the Registrant's common stock, which is contained in a registration statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1560293/000157587222000322/cm057_8a-12b.htm) filed with the SEC on April 26, 2022 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

In addition, all documents subsequently filed by the Registrant with the SEC pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents. The Registrant is not incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed "filed" with the SEC.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit<br> Number** | **Description** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed<br> Herewith** |
| **Exhibit<br> Number** | **Description** | **Schedule<br> Form** | **File<br> Number** | **Exhibit** | **Filing Date** | **Filed<br> Herewith** |
| 4.1 | [Second Amended and Restated Certificate of Incorporation of the Registrant, filed on April 10, 2023](http://www.sec.gov/Archives/edgar/data/1560293/000157587223000672/cm307_ex3-1.htm) | S-3 | 333-271648 | 3.1 | May 4, 2023 |  |
| 4.2 | [Certificate of Correction to Second Amended and Restated Certificate of Incorporation of the Registrant, filed on October 25, 2023](https://www.sec.gov/Archives/edgar/data/1560293/000121390025097880/ea026057901ex4-2_tenon.htm) | S-8 | 333-290808 | 4.2 | October 10, 2025 |  |
| 4.3 | [Amendment to Certificate of Incorporation Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of the Registrant, filed on November 1, 2023](http://www.sec.gov/Archives/edgar/data/1560293/000121390023084331/ea187680ex3-1_tenonmed.htm) | 8-K | n/a | 3.1 | November 7, 2023 |  |
| 4.4 | [Amendment to Certificate of Incorporation Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of the Registrant, filed on September 4, 2024](https://www.sec.gov/Archives/edgar/data/1560293/000121390025097880/ea026057901ex4-4_tenon.htm) | S-8 | 333-290808 | 4.4 | October 10, 2025 |  |
| 4.5 | [Certificate of Designations, Rights and Preferences for Series A Preferred Stock of the Registrant, filed on February 20, 2024](http://www.sec.gov/Archives/edgar/data/1560293/000121390024016218/ea0200461ex10-2_tenonmed.htm) | 8-K | n/a | 10.2 | February 22, 2024 |  |
| 4.6 | [Amendment to Certificate of Designations, Rights and Preferences for Series A Preferred Stock, filed on September 5, 2024](https://www.sec.gov/Archives/edgar/data/1560293/000121390025097880/ea026057901ex4-6_tenon.htm) | S-8 | 333-290808 | 4.6 | October 10, 2025 |  |
| 4.7 | [Certificate of Designations, Rights and Preferences for Series B Preferred Stock, filed on September 5, 2024](https://www.sec.gov/Archives/edgar/data/1560293/000121390025097880/ea026057901ex4-7_tenon.htm) | S-8 | 333-290808 | 4.7 | October 10, 2025 |  |
| 4.8 | [Bylaws of the Registrant](http://www.sec.gov/Archives/edgar/data/1560293/000157587221000314/tm005_ex3-2.htm) | S-1/A | 333-260931 | 3.2 | April 20, 2022 |  |
| 4.9 | [Tenon Medical, Inc. 2022 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1560293/000157587222000257/cm042_ex10-30.htm) | S-1/A | 333-260931 | 10.30 | April 20, 2022 |  |
| 4.10 | [<u>Amendment to Tenon Medical, Inc. 2022 Equity Incentive Plan, dated as of July 23, 2024</u>](ea027550101ex4-10_tenon.htm) |  |  |  |  | **X** |
| 4.11 | [Amendment to Tenon Medical, Inc. 2022 Equity Incentive Plan, dated as of September 18, 2025](https://www.sec.gov/Archives/edgar/data/1560293/000121390025097880/ea026057901ex4-10_tenon.htm) | S-8 | 333-290808 | 4.10 | October 10, 2025 |  |
| 5.1 | [Opinion of Sichenzia Ross Ference Carmel LLP](ea027550101ex5-1_tenon.htm) |  |  |  |  | **X** |
| 23.1 | [Consent of Haskell & White LLP](ea027550101ex23-1_tenon.htm) |  |  |  |  | **X** |
| 23.2 | [Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1)](ea027550101ex5-1_tenon.htm) |  |  |  |  | **X** |
| 24.1 | [Power of Attorney (included in the signature pages hereto)](#ten_021) |  |  |  |  | **X** |
| 107 | [Filing Fee Table](ea027550101ex-fee_tenon.htm) |  |  |  |  | **X** |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Registration Statement and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of Los Gatos, State of California, on the 12<sup>th</sup> day of February 2026.

---

| | |
|:---|:---|
| **TENON MEDICAL, INC.** | **TENON MEDICAL, INC.** |
| By: | */s/ Steven M. Foster* |
| Name: | Steven M. Foster |
| Title: | Chief Executive Officer and President<br> (Principal Executive Officer) |

---

KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints Steven M. Foster, Kevin Williamson, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or his or her substitutes or substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Steven M. Foster* | Chief Executive Officer, and President, Director | February 12, 2026 |
| Steven M. Foster | (Principal Executive Officer) |  |
| */s/ Kevin Williamson* | Chief Financial Officer | February 12, 2026 |
| Kevin Williamson | (Chief Financial and Accounting Officer) |  |
| */s/ Richard Ferrari* | Director | February 12, 2026 |
| Richard Ferrari |  |  |
| */s/ Richard Ginn* | Chief Technology Officer and Director | February 12, 2026 |
| Richard Ginn |  |  |
| */s/ Stephen Hochschuler, MD* | Director | February 12, 2026 |
| Stephen Hochschuler, MD |  |  |
| */s/ Ivan Howard* | Director | February 12, 2026 |
| Ivan Howard |  |  |
| */s/ Kristine Jacques* | Director | February 12, 2026 |
| Kristine Jacques |  |  |
| */s/ Robert Weigle* | Director | February 12, 2026 |
| Robert Weigle |  |  |

---

## Exhibit 4.10

**Exhibit 4.10**

**AMENDMENT TO TENON MEDICAL, INC. 2022 EQUITY INCENTIVE PLAN**

July 23, 2024

Subject to the approval of the stockholders (the "<u>Stockholder Approval</u>") of Tenon Medical, Inc., a Delaware corporation (the "<u>Company</u>"), at the Company's 2024 Annual Meeting of Stockholders, the Tenon Medical, Inc. 2022 Equity Incentive Plan (the "<u>2022 Plan</u>") is hereby amended as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Section 3</u>. Sections 3.1 and 3.2 of the 2022 Plan are hereby amended and restated in its entirety as follows:

"3.1 **Stock Subject to the Plan**. Subject to adjustment upon changes in capitalization of the Company as provided in Section 15 of the Plan and the automatic increase set forth in Section 3.2 of the Plan, the maximum aggregate number of Shares that may be subject to Awards and sold under the Plan will be equal to 1,408,959 Shares. In addition, Shares may become available for issuance under Section 3.2 of the Plan. The Shares may be authorized but unissued, or reacquired Common Stock.

"3.2 **Automatic Share Reserve Increase**. Subject to adjustment upon changes in capitalization of the Company as provided in Section 15, the number of Shares available for issuance under the Plan will be increased on the first day of each Fiscal Year beginning with the 2025 Fiscal Year, in an amount equal to the least of (a) 2,200,000 Shares, (b) a number of Shares equal to four percent (4%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding Fiscal Year, and (c) such number of Shares determined by the Administrator no later than the last day of the immediately preceding Fiscal Year."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Section 2.12</u>. Section 2.12 of the 2022 Plan is hereby amended and restated in its entirety as follows:

"2.12 "**Consultant**" means any natural person, including an advisor, or any legal entity, engaged by the Company or any of its Parent or Subsidiaries to render bona fide services to such entity, provided the services (a) are not in connection with the offer or sale of securities in a capital-raising transaction, and (b) do not directly promote or maintain a market for the Company's securities."

Except as expressly amended hereby, the terms of the 2022 Plan shall be and remain unchanged and the 2022 Plan as amended hereby shall remain in full force and effect.

IN WITNESS WHEREOF, the Company has caused this Amendment to be executed by its duly authorized representative on the day and year first above written.

---

| | |
|:---|:---|
| TENON MEDICAL, INC. | TENON MEDICAL, INC. |
| By: | /s/ Steven Foster |
| Name: | Steven Foster |
| Title: | Chief Executive Officer and President |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

February 12, 2026

Tenon Medical, Inc.

104 Cooper Ct.

Los Gatos, CA 95032

RE: Tenon Medical, Inc. <br>Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to Tenon Medical, Inc., a Delaware corporation (the "***Company***"), in connection with the Registration Statement on Form S-8 (as amended, the "***Registration Statement***"), filed by the Company with the Securities and Exchange Commission (the "***Commission***") pursuant to the Securities Act of 1933, as amended (the "***Securities Act***") in connection with the offer and sale by the Company of an additional 445,100 shares of common stock, par value $0.001 per share (the "***Shares***"), issuable in connection with the Company's Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended ("***Plan***").

In connection with our opinion expressed below we have examined originals or copies of the Company's Second Amended and Restated Certificate of Incorporation, as amended, filed with the Secretary of State of the State of Delaware (the "***Certificate of Incorporation***") and the Company's Bylaws (the "***Bylaws***" and, together with the Certificate of Incorporation, the "***Charter Documents***"), the Registration Statement, together with the exhibits filed as a part thereof and all other documents incorporated therein by reference, the registration statements incorporated by reference in the Registration Statement, certain corporate proceedings of the Company's board of directors or a committee or committees of the Board relating to the Registration Statement, and such other agreements, documents, certificates and statements of the Company, and public or government officials, as we have deemed advisable, and have examined such questions of law as we have considered necessary.

We have assumed, and express no opinion as to, the genuineness of all signatures on documents submitted to us, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity of all persons or entities executing the same, the absence of any termination, modification, waiver or amendment to any document reviewed by us, the absence of any other extrinsic agreements or documents that might change or affect the interpretation or terms of documents we have reviewed, and the due authorization, execution and delivery of all such documents where due authorization, execution and delivery are prerequisites to the effectiveness thereof.

Our opinion is expressed only with respect to the Delaware General Corporation Law (the "***DGCL***"). We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan and the Registration Statement, will be validly issued, fully paid, and nonassessable.

Based upon the foregoing and subject to the qualifications and assumptions stated herein, we are of the opinion that the Shares have been duly authorized by all requisite corporate action on the part of the Company under the DGCL and when the Shares are issued to the eligible individuals in accordance with the terms and conditions of the Plan and the applicable award agreement for consideration in an amount at least equal to the par value of such Shares, the Shares will be validly issued, fully paid and nonassessable.

We assume no obligation to update or supplement any of our opinions to reflect any changes of law or fact that may occur. We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving our consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

---

| |
|:---|
| Very truly yours, |
| */s/ Sichenzia Ross Ference Carmel LLP* |
| Sichenzia Ross Ference Carmel LLP |

---

1185 AVENUE OF THE AMERICAS \| 31ST FLOOR \| NEW YORK, NY \| 10036

T (212) 930-9700 \| F (212) 930-9725 \| WWW.SRFC.LAW

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Tenon Medical, Inc. (the "Company") of our report dated March 26, 2025, relating to our audits of the Company's consolidated financial statements as of December 31, 2024 and 2023, and for each of the years then ended, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which report includes an explanatory paragraph expressing substantial doubt regarding the Company's ability to continue as a going concern.

---

| | |
|:---|:---|
|  | */s/ Haskell & White LLP* |
|  | HASKELL & WHITE LLP |
| Irvine, California |  |
| February 11, 2026 |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**TENON MEDICAL, INC**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common stock, par value $0.001 each, to be issued pursuant to the Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended | (1) | Other | 445100 | $0.67 | $298217.00 | 0.0001381 | $41.18 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $298217.00 |  | 41.18 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $41.18 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) This Registration Statement on Form S-8 (this "Registration Statement") covers additional shares of Common Stock, par value $0.001 per share ("Common Stock"), of Tenon Medical, Inc. (the "Company" or "Registrant") (i) authorized for issuance under the Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan") and (ii) pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), any additional shares of Common Stock that may become issuable under the 2022 Plan by reason of any stock split, stock dividend or similar transaction involving the Common Stock. Proposed maximum offering price per share was estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) promulgated under the Securities Act. The proposed maximum offering price per share and the maximum aggregate offering price are based upon $0.67 per share, which is the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Capital Market on February 6, 2026. Maximum aggregate offering price was rounded up to the nearest cent.